Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 135 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 135 @ $71.5 vs 2 OI; Earnings 2/26 Before Open Ref=$346.69

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 213 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 213 @ $67.5 vs 2 OI; Earnings 2/26 Before Open Ref=$343.8

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 vs 2 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 @ $67.5 vs 2 OI; Earnings 2/26 Before Open Ref=$343.8

Madrigal Pharmaceuticals Option Alert: Jul 18 $320 Calls at the Bid: 100 @ $65.5 vs 2 OI; Earnings 2/26 Before Open Ref=$342.44

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Ask: 242 vs 2593 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Ask: 242 @ $55.5 vs 2593 OI; Earnings 2/26 Before Open Ref=$339.38

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls Sweep (45) near the Bid: 173 vs 2593 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls Sweep (45) near the Bid: 173 @ $56.034 vs 2593 OI; Earnings 2/26 Before Open Ref=$337.92

Madrigal Pharmaceuticals Option Alert: Mar 21 $320 Calls at the Ask: 923 vs 949 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Mar 21 $320 Calls at the Ask: 923 @ $36.0 vs 949 OI; Earnings 2/26 Before Open Ref=$335.69

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 99 vs 2484 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 99 @ $59.0 vs 2484 OI; Earnings 2/26 Before Open Ref=$338.91

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 100 vs 2394 OI; Earnings 2/26 Before Open 

Madrigal Pharmaceuticals Option Alert: Apr 17 $300 Calls at the Bid: 100 @ $62.8 vs 2394 OI; Earnings 2/26 Before Open Ref=$340.52

Madrigal Pharmaceuticals Bolsa (NASDAQ: MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL) Bolsa

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals Inc

Pet Valu Hldgs (CSE2: PET) is looking for FY2025 Adj EPS of $1.60-$1.66 vs $1.61 analyst estimate. sees sales of $1.170 billion-$1.200 billion vs $1.17 billion analyst estimate.

News

Guidance

Pet Valu Hldgs Sees FY2025 Adj EPS CAD $1.60-$1.66 vs $1.61 Est; Sees Sales CAD $1.170B-$1.200B vs $1.17B Est

"During February, we saw record performance around Valentines Day. However, our topline performance for the month was soft, as uncharacteristically cold weather across the U.S. affected apparel sales, and declining consumer confidence impacted our discretionary assortment overall," said Jim Lee, chief financial officer.&nbsp;
"Looking ahead, we expect to see a moderation in this trend as apparel sales respond to warmer weather around the country, and consumers turn to Target for upcoming seasonal moments such as the Easter holiday. &nbsp;We will continue to monitor these trends and will remain appropriately cautious with our expectations for the year ahead."

Target Expects Meaningful YoY Profit Pressure In Q1 Relative To Remainder Of The Year, In Light Of Ongoing Consumer Uncertainty And Small Decline In February Sales, Combined With Tariff Uncertainty

Target Said In Light Of Ongoing Consumer Uncertainty, Small Decline In February Net Sales, Tariff Uncertainty, Expected Timing Of Certain Costs Within FY, Expect To See Meaningful Year-over-Year Profit Pressure In Q1 Relative To Remainder Of Year

HC Wainwright &amp; Co. analyst Edward White reiterates TG Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) with a Buy and maintains $55 price target.

Price Target

Reiteration

Analyst Ratings

TGTX

HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $55 Price Target

Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) ("Sea" or the "Company") today announced its financial results for the fourth quarter and full year ended December 31, 2024.
"We delivered a great 2024 with all three businesses going back to strong, double-digit growth, exceeding our original guidance. It was also our second consecutive year of annual positive profit, with all three of our businesses recording positive adjusted EBITDA," said Forrest Li, Sea's Chairman and Chief Executive Officer.
On e-commerce, he said, "GMV grew 28% year-on-year to surpass US$100 billion, and we achieved adjusted EBITDA profitability in both Asia and Brazil. We remain confident about our ability to continue delivering profitable growth in 2025 and expect Shopee's full year 2025 GMV growth to be around 20%, with improving profitability."
Regarding digital financial services, Mr. Li shared, "We delivered exceptional loan book growth of more than 60% year-on-year in the fourth quarter, surpassing US$5 billion as of the end of 2024, making us one of the largest consumer lending businesses in Southeast Asia. While we have scaled fast, risk management remains to be our top operational priority. In 2025, we expect loan book size to grow meaningfully faster than Shopee's GMV annual growth rate, as we improve credit penetration both on- and off-Shopee."
On digital entertainment, Mr. Li said, "2024 was a great year for Garena, marking Free Fire's remarkable comeback with annual bookings growing at 34% year-on-year. Looking ahead into 2025, we will continue scaling our user base and broadening our content offerings. We now expect Garena to grow double digit year-on-year, for both user base and bookings in 2025."

Sea Expects Shopee's 2025 GMV Growth Of ~20% With Improving Profitability And Garena To Grow Double DigitFor Both User Base And Bookings

UBS analyst Manav Gupta downgrades Green Plains (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) from Buy to Neutral and announces $7 price target.

Downgrades

GPRE

UBS Downgrades Green Plains to Neutral, Announces $7 Price Target

Health Care

General

NNVC

NanoViricides' NV-387 Promises To Be An Effective Drug To Treat Measles

Pet Valu Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PET#TSX">PET</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.40 by 12.5 percent. This is a 16.67 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $295.15 million which beat the analyst consensus estimate of $291.97 million by 1.09 percent. This is a 2.87 percent increase over sales of $286.91 million the same period last year.

Earnings

Earnings Beats

TSX:PET

Pet Valu Hldgs Q4 Adj CAD $0.45 Beats $0.40 Estimate, Sales CAD $295.15M Beat $291.97M Estimate

The Company has the following expectations for full-year 2025:
<ul>
<li>A modest increase in the Company's operating margin rate compared to full-year 2024</li>
<li>An effective tax rate of 23 to 24 percent</li>
</ul>

Target Expects FY25 Net Sales Growth In Range Around 1%, Reflecting Comparable Sales Growth Around Flat; Adjusted EPS Of $8.80 - $9.80 (Est $9.31)

InfuSystem is providing annual guidance for the full year 2025 with net revenue growth estimated to be in the 8% to 10% range. We are also forecasting Adjusted EBITDA margin (non-GAAP) to be in the high-teens, exceeding the Company's margin of 18.8% in 2024, this despite the planned continued investment in the Company's information technology systems. The Company intends to update its annual guidance throughout the year.&nbsp;

INFU

InfuSystem Estimates 2025 With Net Revenue Growth Of 8% To 10%, With Adjusted EBITDA Margin To Be In The High-Teens

UBS analyst William Grippin downgrades Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) from Buy to Neutral and lowers the price target from $5 to $0.65.

NOVA

UBS Downgrades Sunnova Energy Intl to Neutral, Lowers Price Target to $0.65

HC Wainwright &amp; Co. analyst Edward White reiterates Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and maintains $51 price target.

SNDX

HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $51 Price Target

Target Reports Q4 Comparable Sales Growth Of 1.5%, Reflected Strong Traffic And Digital Performance

Earnings Misses

Sea Q4 2024 GAAP EPS $0.39 Misses $0.40 Estimate, Sales $4.950B Beat $4.623B Estimate

InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.07 by 42.86 percent. The company reported quarterly sales of $33.85 million which missed the analyst consensus estimate of $34.90 million by 3.02 percent. This is a 6.54 percent increase over sales of $31.77 million the same period last year.

InfuSystems Holdings Q4 2024 GAAP EPS $0.04 Misses $0.07 Estimate, Sales $33.85M Miss $34.90M Estimate

AI Detection firm, Copyleaks has found that the text generated by DeepSeek-R1 and OpenAI&#8217;s ChatGPT has &#8220;Stylistic overlaps&#8221; in 74.2% of instances.
What Happened: A study conducted by Copyleaks showed that Chinese start-up firm, DeepSeek-R1&#8217;s text generation closely mirrored OpenAI&#8217;s style in over 74% of cases. This suggests that DeepSeek may have relied on OpenAI's model during its training without authorization, according to the report.
The study employed three AI classifiers to accurately analyze stylistic fingerprints, allowing for model-specific attribution. This plays a vital role in safeguarding intellectual property and fostering ethical AI development.
DeepSeek and OpenAI did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
Interestingly, the written text produced by most other models was easily identifiable as unique to each one, except DeepSeek. For instance, Microsoft&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Phi-4 and Grok-1 models exhibited no similarities to existing models, confirming it was trained independently.
The majority of DeepSeek&#8217;s outputs were identified as being generated by OpenAI&#8217;s models. &nbsp;&#8220;While this similarity doesn&#8217;t&nbsp;definitively prove or declare DeepSeek&nbsp;as a derivative, it does&nbsp;raise questions about its development,&#8221; said&nbsp;Shai Nisan,&nbsp;Head of data science at&nbsp;Copyleaks.
SEE ALSO: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44075328/eric-trump-says-timing-of-strategic-bitcoin-xrp-cardano-reserve-announcement-was-a-win-for-retail-investors">Eric Trump Says Timing Of Strategic Bitcoin, XRP, Cardano Reserve Announcement Was A &#8216;Win&#8217; For Retail Investors</a>
Why It Matters: This revelation comes at a time when the AI industry is under scrutiny. Recently, Singapore authorities launched an investigation into potential <a href="https://www.benzinga.com/25/03/44076579/singapore-investigates-potential-fraud-in-nvidia-ai-chip-shipments-the-question-is-whether-malaysia-was-a-final-destination">fraudulent activities </a>related to the shipment of&nbsp;Nvidia Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips.
Furthermore,&nbsp;Dario Amodei, CEO of Jeff Bezos-backed Anthropic, has called for stronger U.S. AI safeguards. He warned that autocratic regimes like <a href="https://www.benzinga.com/25/03/44069535/anthropic-ceo-dario-amodei-pushes-for-stronger-us-ai-safeguards-saying-autocracies-like-china-and-russia-could-use-ai-to-expand-their-power">China and Russia </a>could use AI to enhance their control and military capabilities.
While the possibility of both AI models being trained using intersecting datasets cannot be ruled out, there could be deeper nuances. "Even if large language models draw from overlapping datasets, AI fingerprinting remains crucial. The sheer variety of elements—such as architecture, fine-tuning methods and generation techniques—ensures that each LLM develops a distinct writing style,&#8221; explains Nisan.
The DeepSeek-R1 and OpenAI similarity issue underscores the need for clear regulations and transparency in AI development to prevent potential misuse and protect intellectual property. It also brings into question DeepSeek R1&#8217;s perceived level of innovation.
Nisan cautioned that this could have significant implications for the AI industry, if not regulated.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/25/03/44101621/deepseek-loses-top-spot-as-tencents-yuanbao-ai-becomes-no-1-iphone-app-amid-intensifying-ai-battle">DeepSeek Loses Top Spot As Tencent&#8217;s Yuanbao AI Becomes The Top iPhone App In China Amid Intensifying AI Battle</a></li>
</ul>
Image Via Midjourney, Shutterstock

Equities

Markets

Tech

MSFT

NVDA

74% Of DeepSeek's Output Mimics OpenAI's ChatGPT, New Study Reveals: 'It Does Raise Questions About Its Development'

Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) reported quarterly earnings of $2.41 per share which beat the analyst consensus estimate of $2.26 by 6.64 percent. This is a 19.13 percent decrease over earnings of $2.98 per share from the same period last year. The company reported quarterly sales of $30.91 billion which beat the analyst consensus estimate of $30.84 billion by 0.23 percent. This is a 3.15 percent decrease over sales of $31.92 billion the same period last year.

Target Q4 2024 Adj EPS $2.41 Beats $2.26 Estimate, Sales $30.91B Beat $30.84B Estimate

UBS analyst William Grippin downgrades Ameresco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMRC#NYSE">AMRC</a>) from Buy to Sell and lowers the price target from $37 to $8.

AMRC

UBS Downgrades Ameresco to Sell, Lowers Price Target to $8

HC Wainwright &amp; Co. analyst Mike Colonnese maintains Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and lowers the price target from $35 to $30.

HC Wainwright & Co. Maintains Buy on Hut 8, Lowers Price Target to $30

<a href="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197" title="https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197">https://www.wsj.com/business/deals/honeywells-transformation-continues-with-2-2-billion-deal-for-pump-maker-b4695197</a>

Wall Street Journal Reported Honeywell Nears $2.2B All-Cash Deal to Acquire Pump Maker Sundyne From Warburg Pincus, Announcement Expected Tuesday

Press Releases

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra™ (resmetirom) in Patients with Compensated MASH Cirrhosis

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
03:51 PMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	135	675	135	33750	2	TRADE	BEARISH
10:19 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	135	186	213	9300	2	TRADE	BEARISH
10:19 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	135	186	100	9300	2	TRADE	BEARISH
10:11 AMFeb 20, 2025	CALL	$320.00	Jul 18, 2025	135	150	100	7500	2	TRADE	BEARISH
10:08 AMFeb 20, 2025	CALL	$300.00	Apr 17, 2025	43	263	242	10	2593	TRADE	BULLISH
10:07 AMFeb 20, 2025	CALL	$300.00	Apr 17, 2025	43	1	173	0	2593	SWEEP	BEARISH
03:11 PMFeb 19, 2025	CALL	$320.00	Mar 21, 2025	16	185	923	19	949	TRADE	BULLISH
11:19 AMFeb 18, 2025	CALL	$300.00	Apr 17, 2025	43	104	99	4	2484	TRADE	BEARISH
03:01 PMFeb 14, 2025	CALL	$300.00	Apr 17, 2025	43	112	100	5	2394	TRADE	BEARISH

Comments

Madrigal Pharmaceuticals

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL